DDInter255 DDInter997
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition. Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms.
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Busulfan {u} (Compound) causes {v} (Side Effect) Infestation
Infestation {u} (Side Effect) is caused by {v} (Compound) Ivacaftor
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Busulfan {u} (Compound) causes {v} (Side Effect) Infestation
Infestation {u} (Side Effect) is caused by {v} (Compound) Escitalopram
Escitalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Busulfan {u} (Compound) causes {v} (Side Effect) Infestation
Infestation {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Busulfan {u} (Compound) causes {v} (Side Effect) Transaminases increased
Transaminases increased {u} (Side Effect) is caused by {v} (Compound) Apixaban
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Busulfan {u} (Compound) downregulates {v} (Gene) COTL1
COTL1 {u} (Gene) is regulated by {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Busulfan {u} (Compound) downregulates {v} (Gene) COTL1
COTL1 {u} (Gene) is downregulated by {v} (Compound) Escitalopram
Escitalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Busulfan (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Ivacaftor (Compound)
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Busulfan (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Escitalopram (Compound) and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Busulfan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with ABCB1 (Gene) and ABCB1 (Gene) is bound by Ivacaftor (Compound)
Busulfan (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Busulfan (Compound) causes Transaminases increased (Side Effect) and Transaminases increased (Side Effect) is caused by Apixaban (Compound) and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Busulfan (Compound) downregulates COTL1 (Gene) and COTL1 (Gene) is regulated by ABCB1 (Gene) and ABCB1 (Gene) is bound by Ivacaftor (Compound)
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Busulfan (Compound) downregulates COTL1 (Gene) and COTL1 (Gene) is downregulated by Escitalopram (Compound) and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Ivacaftor